These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

551 related articles for article (PubMed ID: 12231533)

  • 1. Two-hit inactivation of FHIT by loss of heterozygosity and hypermethylation in breast cancer.
    Yang Q; Nakamura M; Nakamura Y; Yoshimura G; Suzuma T; Umemura T; Shimizu Y; Mori I; Sakurai T; Kakudo K
    Clin Cancer Res; 2002 Sep; 8(9):2890-3. PubMed ID: 12231533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduced Fhit expression in sporadic and BRCA2-linked breast carcinomas.
    Ingvarsson S; Agnarsson BA; Sigbjornsdottir BI; Kononen J; Kallioniemi OP; Barkardottir RB; Kovatich AJ; Schwarting R; Hauck WW; Huebner K; McCue PA
    Cancer Res; 1999 Jun; 59(11):2682-9. PubMed ID: 10363992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of fragile histidine triad gene expression in advanced lung cancer is consequent to allelic loss at 3p14 locus and promoter methylation.
    Wali A; Srinivasan R; Shabnam MS; Majumdar S; Joshi K; Behera D
    Mol Cancer Res; 2006 Feb; 4(2):93-9. PubMed ID: 16513840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allelic loss on chromosome 3p21.3 and promoter hypermethylation of semaphorin 3B in non-small cell lung cancer.
    Kuroki T; Trapasso F; Yendamuri S; Matsuyama A; Alder H; Williams NN; Kaiser LR; Croce CM
    Cancer Res; 2003 Jun; 63(12):3352-5. PubMed ID: 12810670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of the FHIT gene and FRA3B region in sporadic breast cancer, preneoplastic lesions, and familial breast cancer probands.
    Ahmadian M; Wistuba II; Fong KM; Behrens C; Kodagoda DR; Saboorian MH; Shay J; Tomlinson GE; Blum J; Minna JD; Gazdar AF
    Cancer Res; 1997 Sep; 57(17):3664-8. PubMed ID: 9288768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Promoter methylation and loss of coding exons of the fragile histidine triad (FHIT) gene in intrahepatic cholangiocarcinomas.
    Foja S; Goldberg M; Schagdarsurengin U; Dammann R; Tannapfel A; Ballhausen WG
    Liver Int; 2005 Dec; 25(6):1202-8. PubMed ID: 16343073
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Fragile Histidine Triad gene and breast cancer.
    Yang Q; Yoshimura G; Sakurai T; Kakudo K
    Med Sci Monit; 2002 Jul; 8(7):RA140-4. PubMed ID: 12118213
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypermethylation and loss of heterozygosity of tumor suppressor genes on chromosome 3p in cervical cancer.
    Choi CH; Lee KM; Choi JJ; Kim TJ; Kim WY; Lee JW; Lee SJ; Lee JH; Bae DS; Kim BG
    Cancer Lett; 2007 Sep; 255(1):26-33. PubMed ID: 17467893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 5'CpG island hypermethylation and aberrant transcript splicing both contribute to the inactivation of the FHIT gene in resected non-small cell lung cancer.
    Tzao C; Tsai HY; Chen JT; Chen CY; Wang YC
    Eur J Cancer; 2004 Sep; 40(14):2175-83. PubMed ID: 15341994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frequent FHIT gene loss of heterozygosity in human papillomavirus-infected non-smoking female lung cancer in Taiwan.
    Wang J; Cheng YW; Wu DW; Chen JT; Chen CY; Chou MC; Lee H
    Cancer Lett; 2006 Apr; 235(1):18-25. PubMed ID: 15935551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Hypermethylation of fragile histidine triad gene and 3p14 allelic deletion in ovarian carcinomas].
    Hong FZ; Wang B; Li HM; Liew CT
    Zhonghua Bing Li Xue Za Zhi; 2005 May; 34(5):257-61. PubMed ID: 16181544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inactivation of the p16 gene by hypermethylation and loss of heterozygosity in adenocarcinoma of the lung.
    Awaya H; Takeshima Y; Amatya VJ; Furonaka O; Tagawa K; Kohno N; Inai K
    Pathol Int; 2004 Jul; 54(7):486-9. PubMed ID: 15189501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fragile genes as biomarkers: epigenetic control of WWOX and FHIT in lung, breast and bladder cancer.
    Iliopoulos D; Guler G; Han SY; Johnston D; Druck T; McCorkell KA; Palazzo J; McCue PA; Baffa R; Huebner K
    Oncogene; 2005 Feb; 24(9):1625-33. PubMed ID: 15674328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicopathological significance of epigenetic inactivation of RASSF1A at 3p21.3 in stage I lung adenocarcinoma.
    Tomizawa Y; Kohno T; Kondo H; Otsuka A; Nishioka M; Niki T; Yamada T; Maeshima A; Yoshimura K; Saito R; Minna JD; Yokota J
    Clin Cancer Res; 2002 Jul; 8(7):2362-8. PubMed ID: 12114441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Correlation between methylation of 5'-CpG islands and inactivation of FHIT gene in cervical cancer].
    Shi HR; Wu QH; Suo ZH; Nesland JM
    Ai Zheng; 2005 Jan; 24(1):7-11. PubMed ID: 15642192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FHIT gene and flanking region on chromosome 3p are subjected to extensive allelic loss in Egyptian breast cancer patients.
    Ismail HM; Medhat AM; Karim AM; Zakhary NI
    Mol Carcinog; 2011 Aug; 50(8):625-34. PubMed ID: 21557333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frequent silencing of fragile histidine triad gene (FHIT) in Burkitt's lymphoma is associated with aberrant hypermethylation.
    Hussain A; Gutiérrez MI; Timson G; Siraj AK; Deambrogi C; Al-Rasheed M; Gaidano G; Magrath I; Bhatia K
    Genes Chromosomes Cancer; 2004 Dec; 41(4):321-9. PubMed ID: 15384174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epigenetic silencing contributes to frequent loss of the fragile histidine triad tumour suppressor in basal cell carcinomas.
    Goldberg M; Rummelt C; Laerm A; Helmbold P; Holbach LM; Ballhausen WG
    Br J Dermatol; 2006 Dec; 155(6):1154-8. PubMed ID: 17107382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FHIT expression and hypermethylation in esophageal squamous cell carcinoma.
    Noguchi T; Takeno S; Kimura Y; Uchida Y; Daa T; Yokoyama S; Gabbert HE; Mueller W
    Int J Mol Med; 2003 Apr; 11(4):441-7. PubMed ID: 12632095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of Msh2 is not associated with FHIT deletion in breast carcinomas.
    Yang Q; Nakamura Y; Nakamura M; Yoshimura G; Suzuma T; Umemura T; Mori I; Sakurai T; Kakudo K
    Anticancer Res; 2002; 22(5):2591-5. PubMed ID: 12529969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.